Triple-negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Triple-negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2018-08-28Clinical Trial Update: Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes [Phase 3]
Phase 3 trial comparing eribulin to vinorelbine in locally recurrent or metastatic breast cancer after anthracycline and taxane treatment ha…
-
CLINICAL_TRIALS trial_result · 2018-08-22Clinical Trial Update: Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer [Phase 2]
Phase 2 study assessing the safety and efficacy of enzalutamide in patients with advanced, androgen receptor-positive triple-negative breast…
-
CLINICAL_TRIALS trial_result · 2018-07-23Clinical Trial Update: MUC1 Vaccine for Triple-negative Breast Cancer [EARLY_Phase 1]
An early-phase Phase 1 trial evaluating a MUC1 vaccine for breast cancer has completed its evaluation. The study targets inflammatory breast…
-
CLINICAL_TRIALS trial_result · 2018-06-29Clinical Trial Update: Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy [Phase 1]
This Phase 1 study of veliparib in patients with malignant solid tumors that did not respond to prior therapy has completed.
-
CLINICAL_TRIALS trial_result · 2018-05-18Clinical Trial Update: Phase II Pilot Study Assessing Efficacy of a Cisplatin - Metronomic Cyclophosphamide Treatment in Patients With Metastatic Triple Negative Breast Cancer Resistant to Anthracyclines and Taxanes [Phase 2]
Phase II pilot study evaluating cisplatin plus metronomic cyclophosphamide in metastatic triple-negative breast cancer resistant to anthracy…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-04-30Clinical Trial Update: A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer [Phase 1]
A Phase 1 study evaluating varlilumab in combination with atezolizumab in patients with advanced cancers has been terminated.
-
CLINICAL_TRIALS trial_result · 2018-03-30Clinical Trial Update: A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor [Phase 1]
A Phase 1 trial evaluating the safety and pharmacokinetics of ABBV-221 in adults with advanced solid tumors likely to overexpress EGFR was t…
-
CLINICAL_TRIALS trial_result · 2018-03-30Clinical Trial Update: Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer [Phase 1]
Phase 1 study evaluating the combination of dinaciclib and epirubicin hydrochloride in metastatic triple-negative breast cancer has complete…
-
CLINICAL_TRIALS trial_result · 2018-03-22Clinical Trial Update: A Study of Bevacizumab With Taxane Therapy in Participants With Triple Negative Breast Cancer [Phase 4]
Phase 4 study evaluating bevacizumab with taxane therapy in triple-negative breast cancer has completed and posted results.
-
CLINICAL_TRIALS trial_result · 2018-03-21Clinical Trial Update: Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment [Phase 1]
A Phase 1 safety study of the investigational drug MM-151 in patients with advanced solid tumors that have resisted standard treatment has c…
-
CLINICAL_TRIALS trial_result · 2018-03-08Clinical Trial Update: Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) [Phase 2, Phase 3]
This clinical trial update reports final results from a Phase 2/3 study evaluating nab-paclitaxel with gemcitabine and carboplatin versus ge…
-
CLINICAL_TRIALS trial_result · 2018-03-06Clinical Trial Update: Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer [Phase 1]
This update covers completion of a Phase I/II study of AZD2281 (olaparib) in combination with paclitaxel for metastatic triple-negative brea…
-
CLINICAL_TRIALS trial_result · 2018-01-16Clinical Trial Update: Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer [Phase 2]
A phase 2 trial evaluating carboplatin with combination chemotherapy, with or without veliparib, in patients with stage IIB–IIIC breast canc…
-
CLINICAL_TRIALS trial_result · 2017-10-25Clinical Trial Update: Study of Neoadjuvant Treatment of Locally Advanced Breast Cancer With CAP Regimen [Phase 2]
A Phase 2 neoadjuvant trial evaluating the CAP regimen (cyclophosphamide, doxorubicin, paclitaxel) for locally advanced breast cancer, inclu…
-
CLINICAL_TRIALS trial_result · 2017-10-24Clinical Trial Update: Addition of Vismodegib to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients [Phase 2]
A Phase 2 trial evaluating adding vismodegib to neoadjuvant chemotherapy in triple-negative breast cancer patients; the trial status is unkn…
-
CLINICAL_TRIALS trial_result · 2017-09-13Clinical Trial Update: Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer [Phase 2]
A completed Phase 2 trial evaluating Abraxane with or without Tigatuzumab in metastatic triple-negative breast cancer. Results have been pos…
-
CLINICAL_TRIALS trial_result · 2017-08-30Clinical Trial Update: Study of Erlotinib and Metformin in Triple Negative Breast Cancer [Phase 1]
A Phase 1 trial evaluating the combination of Erlotinib and Metformin in triple-negative breast cancer has completed.
-
CLINICAL_TRIALS trial_result · 2017-08-10Clinical Trial Update: Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer [Phase 1]
Phase 1 trial evaluating the combination of veliparib with cisplatin and vinorelbine ditartrate in patients with recurrent and/or metastatic…
-
CLINICAL_TRIALS trial_result · 2017-08-01Clinical Trial Update: Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE) [Phase 2]
Phase 2 GENEVIEVE trial comparing cabazitaxel to weekly paclitaxel as neoadjuvant therapy in specific breast cancer subtypes to assess effic…
-
CLINICAL_TRIALS trial_result · 2017-08-01Clinical Trial Update: MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer [Phase 2]
Phase 2 trial of MK-2206 in breast cancer was terminated, with results posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-06-27Clinical Trial Update: GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer [Phase 1, Phase 2]
A phase 1/2 clinical trial of GDC-0941 (pictilisib) with cisplatin for androgen receptor-negative triple-negative metastatic breast cancer w…
-
CLINICAL_TRIALS trial_result · 2017-06-26Clinical Trial Update: Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC [Phase 2]
Phase 2 study of ENMD-2076, an Aurora and angiogenic kinase inhibitor, in previously treated locally advanced or metastatic triple-negative …
-
CLINICAL_TRIALS trial_result · 2017-06-01Clinical Trial Update: Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response [Phase 2]
This update reports Phase 2 results from a trial of platinum-based chemotherapy in triple-negative metastatic breast cancer and evaluates p6…
-
CLINICAL_TRIALS trial_result · 2017-04-12Clinical Trial Update: A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer [Phase 3]
Phase 3 randomized trial comparing ixabepilone (Ixempra) with paclitaxel (Taxol) as adjuvant therapy for triple-negative breast cancer has c…
-
CLINICAL_TRIALS trial_result · 2017-04-11Clinical Trial Update: Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer [Phase 2]
Phase 2 trial of RO4929097, a gamma-secretase/Notch pathway inhibitor, in advanced/metastatic/recurrent triple-negative breast cancer was te…